Christina Reith

Medicine · Health Sciences

32h-index15.4kcitations72works26.42yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(27), Health Systems, Economic Evaluations, Quality of Life(20), Pharmaceutical Economics and Policy(13), Chronic Kidney Disease and Diabetes(9), Dialysis and Renal Disease Management(7)

Publications58 total

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials
The Lancet·2026Open Access
Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets
Health Technology Assessment·2024· 3 citedOpen Access
Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
Heart·2024· 8 citedOpen Access
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
The Lancet Diabetes & Endocrinology·2024· 111 citedOpen Access
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study
The Lancet Regional Health - Europe·2024· 19 citedOpen Access
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Nature Communications·2024· 8 citedOpen Access
OA-815 A community approach to re-thinking the principles of good randomized controlled trials: informative, respectful, collaborative, feasible and well-managed
2023Open Access
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model
British Journal of General Practice·2023· 7 citedOpen Access
Accelerating clinical trials: time to turn words into action
The Lancet·2023· 4 cited
Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
Kidney International Reports·2023· 2 citedOpen Access
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK
PharmacoEconomics·2023· 18 citedOpen Access
Cost-effectiveness of statin therapy in categories of patients in the UK
European Heart Journal·2022· 2 citedOpen Access
Impact of cardiovascular events on primary and hospital care costs: findings from UK Biobank study
European Heart Journal·2022Open Access
Benefit accrual with cardiovascular disease prevention and effects of discontinuation: a modelling study
European Heart Journal·2022· 2 citedOpen Access
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials
The Lancet·2022· 104 citedOpen Access
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
The Lancet·2022· 222 citedOpen Access
P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data
Value in Health·2022
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
EClinicalMedicine·2021· 68 citedOpen Access
A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts
European Heart Journal·2021Open Access
A pragmatic tool for drug discovery
Drug Discovery Today·2020Open Access
page 1 of 3Next →

Frequent Co-authors

Colin Baigent(46), Jonathan Emberson(44), Martin Landray(30), William G. Herrington(29), Rory Collins(20), Richard Haynes(19), Borislava Mihaylova(17), Alan Cass(16), Bengt Fellström(16), Jane Armitage(16), Anthony Keech(14), John Simes(13), Alastair Gray(13), Hallvard Holdaas(12), Natalie Staplin(12), David C. Wheeler(11), Vera Krane(11), Adeera Levin(11), Iryna Schlackow(11), Lisa Blackwell(10)